Seth Ginsberg: What Patients Need to Know About Biosimilars
Seth Ginsberg, co-founder and president of the Global Healthy Living Foundation, explains what patients should know about biosimilar therapies.
Transcript:
What are the most important things for patients to know about biosimilars?
For people with inflammatory arthritis like rheumatoid arthritis, or other chronic diseases that benefit from biologic medicines such as Crohn disease, psoriasis, [multiple sclerosis, MS], lupus, and others, biosimilars represent new treatment options simply because they are nearly identical to the originator biologic, but not exactly the same.
However, like with every medication, each patient will respond a little differently. Our advice is that patients with arthritis who are prescribed a biologic or biosimilar, track their response to treatment using our ArthritisPower research registry. Patients can download the free app and use it to enter their symptoms and treatment responses. They can also participate in arthritis research. It’s a great tool to understand how you are actually responding to a medicine (and other therapies) over time. Folks can learn more an download the app at www.ArthritisPower.org.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Dr Joseph Alvarnas Highlights the Current State of the Oncology Biosimilar Market
November 9th 2022Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope, explains what the recent FDA approvals of Stimufend and Vegzelma, 2 oncology biosimilars, says about the current state of the oncology biosimilar space.
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
April 12th 2022Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among adalimumab biosimilars when they enter the US market in 2023.
